REEV

REEV operates at the intersection of assistive technology, medical devices, robotics, and healthcare. Its product portfolio spans gait measurement and analysis through REEV SENSE and active mobility assistance through DREEVEN, an AI-powered motorized orthosis intended to support people with neurological gait disorders. This combination links clinical assessment with a potential assistive intervention, while the Neuro-Integration Program provides a route to work with rehabilitation centers. The company is privately held and its latest recorded financing is a seed round, with $12.6 million in total funding. Its disclosed employee range is 11–50. REEV’s stated differentiation is its focus on everyday tasks—including walking, standing, sitting, and stair climbing—and its pairing of wearable robotics with gait analytics. Its competitive position will depend on clinical evidence, usability, regulatory progress, and the ability to translate rehabilitation collaborations into product adoption; public details on these measures remain limited.

REEV’s disclosed financing history shows three rounds: a $120,000 pre-seed round on January 17, 2023, a $3.26 million seed round on July 5, 2023, and a $9.2 million seed round on February 6, 2025. Together, these total approximately $12.58 million, with the 2025 financing representing the clearest capital inflection point. The company’s activity since then has increasingly emphasized clinical development. Its Neuro-Integration Program, announced in April 2026, connected REEV SENSE gait analysis with stroke rehabilitation partners and was designed to prepare for the future introduction of DREEVEN. By September 15, REEV reported that the program had doubled in four months and named three additional clinical collaboration partners. Hiring Lou Awad as Head of Clinical Affairs in April further signals investment in clinical implementation. The next indicators of growth will be demonstrable clinical outcomes, progress toward DREEVEN deployment, and whether the expanded network leads to sustained product use. No later funding round is listed.